Literature DB >> 31141654

The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018-2019.

Oly Ilunga Kalenga1, Matshidiso Moeti1, Annie Sparrow1, Vinh-Kim Nguyen1, Daniel Lucey1, Tedros A Ghebreyesus1.   

Abstract

The international response to the evolving Ebola epidemic in eastern Democratic Republic of Congo (DRC) has had interim successes while facing ongoing difficulties. The outbreak has occurred in an area of intractable conflict among multiple armed groups at a time of contentious national elections. Despite porous international borders and considerable population movement, however, transmission has been confined to North Kivu and Ituri provinces. Factors potentially contributing to this containment include conduct of about 55 million screenings, surveillance of contacts (12,591 under surveillance currently), testing of 280 samples per day, provision of safe and dignified burials for most deaths, vaccination of high-risk people (112,485 vaccinated as of May 7, 2019), and medical treatment including four investigational therapies. Major challenges remain. Since late February 2019, a sharp rise in cases and increased transmission have been observed. These coincide with organized attacks by armed groups targeting response teams, deteriorating security, and the population's increasing distrust of the response effort. The risk of local and regional spread remains high given the high proportion of deaths occurring outside treatment facilities, relatively low proportions of new patients who were known contacts, ongoing nosocomial transmission, and persistent delays in detection and reporting. Stopping this epidemic will require the alignment of the principal political and armed groups in eastern DRC in support of the response.
Copyright © 2019 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31141654     DOI: 10.1056/NEJMsr1904253

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  50 in total

Review 1.  Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases.

Authors:  Rita M Meganck; Ralph S Baric
Journal:  Nat Med       Date:  2021-03-15       Impact factor: 53.440

2.  Ebola Virus Inclusion Body Formation and RNA Synthesis Are Controlled by a Novel Domain of Nucleoprotein Interacting with VP35.

Authors:  Tsuyoshi Miyake; Charlotte M Farley; Benjamin E Neubauer; Thomas P Beddow; Thomas Hoenen; Daniel A Engel
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

3.  The exacerbation of Ebola outbreaks by conflict in the Democratic Republic of the Congo.

Authors:  Chad R Wells; Abhishek Pandey; Martial L Ndeffo Mbah; Bernard-A Gaüzère; Denis Malvy; Burton H Singer; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

Review 4.  The Lancet Commission on diagnostics: transforming access to diagnostics.

Authors:  Kenneth A Fleming; Susan Horton; Michael L Wilson; Rifat Atun; Kristen DeStigter; John Flanigan; Shahin Sayed; Pierrick Adam; Bertha Aguilar; Savvas Andronikou; Catharina Boehme; William Cherniak; Annie Ny Cheung; Bernice Dahn; Lluis Donoso-Bach; Tania Douglas; Patricia Garcia; Sarwat Hussain; Hari S Iyer; Mikashmi Kohli; Alain B Labrique; Lai-Meng Looi; John G Meara; John Nkengasong; Madhukar Pai; Kara-Lee Pool; Kaushik Ramaiya; Lee Schroeder; Devanshi Shah; Richard Sullivan; Bien-Soo Tan; Kamini Walia
Journal:  Lancet       Date:  2021-10-06       Impact factor: 79.321

5.  Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.

Authors:  Thomas R Lane; Sean Ekins
Journal:  ACS Med Chem Lett       Date:  2020-07-23       Impact factor: 4.345

6.  Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.

Authors:  Cassio M Fontes; Barbara D Lipes; Jason Liu; Krystle N Agans; Aiwei Yan; Patricia Shi; Daniela F Cruz; Garrett Kelly; Kelli M Luginbuhl; Daniel Y Joh; Stephanie L Foster; Jacob Heggestad; Angus Hucknall; Maiken H Mikkelsen; Carl F Pieper; Roarke W Horstmeyer; Thomas W Geisbert; Michael D Gunn; Ashutosh Chilkoti
Journal:  Sci Transl Med       Date:  2021-04-07       Impact factor: 17.956

7.  Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A.

Authors:  Kristina Jonsson-Schmunk; Romi Ghose; Maria A Croyle
Journal:  Expert Rev Vaccines       Date:  2021-03-18       Impact factor: 5.217

8.  Key questions for modelling COVID-19 exit strategies.

Authors:  Robin N Thompson; T Déirdre Hollingsworth; Valerie Isham; Daniel Arribas-Bel; Ben Ashby; Tom Britton; Peter Challenor; Lauren H K Chappell; Hannah Clapham; Nik J Cunniffe; A Philip Dawid; Christl A Donnelly; Rosalind M Eggo; Sebastian Funk; Nigel Gilbert; Paul Glendinning; Julia R Gog; William S Hart; Hans Heesterbeek; Thomas House; Matt Keeling; István Z Kiss; Mirjam E Kretzschmar; Alun L Lloyd; Emma S McBryde; James M McCaw; Trevelyan J McKinley; Joel C Miller; Martina Morris; Philip D O'Neill; Kris V Parag; Carl A B Pearson; Lorenzo Pellis; Juliet R C Pulliam; Joshua V Ross; Gianpaolo Scalia Tomba; Bernard W Silverman; Claudio J Struchiner; Michael J Tildesley; Pieter Trapman; Cerian R Webb; Denis Mollison; Olivier Restif
Journal:  Proc Biol Sci       Date:  2020-08-12       Impact factor: 5.349

9.  Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection.

Authors:  Thibaut Jombart; Stéphane Ghozzi; Dirk Schumacher; Timothy J Taylor; Quentin J Leclerc; Mark Jit; Stefan Flasche; Felix Greaves; Tom Ward; Rosalind M Eggo; Emily Nightingale; Sophie Meakin; Oliver J Brady; Graham F Medley; Michael Höhle; W John Edmunds
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-05-31       Impact factor: 6.237

10.  PTSD, depression and anxiety in Ebola virus disease survivors in Beni town, Democratic Republic of the Congo.

Authors:  Célestin Kaputu-Kalala-Malu; Eric Mafuta Musalu; Tim Walker; Olga Ntumba-Tshitenge; Steve Ahuka-Mundeke
Journal:  BMC Psychiatry       Date:  2021-07-08       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.